Affordable Access

Publisher Website

Pulmonary Hemorrhage After Abciximab. Risk Factors and the Role of Protamine

Authors
Publisher
Elsevier Espana
Publication Date
Volume
58
Issue
4
Identifiers
DOI: 10.1016/s1885-5857(06)60676-2
Keywords
  • Abciximab
  • Pulmonary Hemorrhage
  • Coronary Angioplasty
  • Hemorragia Pulmonar
  • Angioplastia Coronaria
Disciplines
  • Biology
  • Medicine

Abstract

Large clinical trials have demonstrated the clinical effectiveness of therapy with inhibitors of the platelet surface-membrane glycoprotein IIb-IIIa receptor in a broad range of patients with ischemic heart disease. Abciximab, a platelet glycoprotein IIb-IIIa receptor blocker, is associated with improved long-term prognosis in patients who require angioplasty and stent placement. Severe bleeding from abciximab use is an uncommon event. We describe a patient with severe pulmonary hemorrhage after treatment with abciximab, and discuss predisposing factors and protamine infusion in this potentially fatal complication.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

[Pulmonary hemorrhage after abciximab. Risk factor...

on Revista Española de Cardiologí... April 2005

Pulmonary Hemorrhage After Percutaneous Coronary I...

on Mayo Clinic Proceedings Jan 01, 2002

Pulmonary hemorrhage after percutaneous coronary i...

on Mayo Clinic Proceedings December 2002

Pulmonary hemorrhage and acute pulmonary thromboem...

on The American Journal of Emerge... February 2013
More articles like this..